Search the database for deliberate release of GM medicinal products
Displaying 1 - 6 of 6
|EU record number
|Company / Sponsor
|Importation of doses of V920 for Emergency Use
|Merck Sharp & Dohme B.V.
|Recombinant Vesicular Stomatitis Virus (rVSV) in which the gene encoding for the VSV glycoprotein G has been deleted and replaced with the gene encoding the Zaire Ebola virus (ZEBOV) glycoprotein (GP).
|A phase IIa partial blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of the Ad5-EBOV in healthy adults aged between 18 and 60 years in Belgium.
|Bejing Institute of Biotechnology, CanSino Biologics Inc,
|Recombinant Adenoviral vector serotype 5 expressing the envelop glycoprotein from Ebola virus (Zaïre-Makona)
|Phase III trial investigating a AAV vector containing a variant of human factor IX gene administered to adult subjects with severe or moderately-severe hemophilia B
|uniQure biopharma B.V.
|Recombinant adeno associated viral vector containing the wild type modified to express the Padua derivative of human coagulation factor IX cDNA
|Only notified under the "contained use" procedure. Dossier submitted on 22/03/2016.
|Phase I study to evaluate the safety and immunogenicity of a bivalent recombinant vaccine against human cytomegalovirus (HCMV).
|Hookipa Biotech AG
|Two replication-deficient lymphocytic choriomeningitidis virus (rLCMV) vectors, one expressing a truncated gBprotein of HCMV and one expressing the pp65 protein of the human CMV
|Only notified under the "contained use" procedure. Dossier submitted on 14/10/2015.
|A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
|Novartis Pharma Services AG
|Chimeric antigen receptor against CD19
|A multi-center, randomized, double-blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination of HIV-1 clade B infected patients under highly antiretroviral therapy
|genes encoding the epitopes of the HIV-1 Gag, Pol and Nef proteins